Mobia Medical shows explosive 113% revenue growth and a bullish insider buy, but a failed momentum gate and a severe recent earnings miss keep the near-term setup risky and unproven.
Thesis pillars
- Earnings Miss Execution Risk→Stable
- Revenue Growth Acceleration→Stable
- Momentum Gate Failure→Stable
- +1 more pillar — see the Why tab for full reasoning
Mobia Medical, Inc. (MOBI) Stock Analysis
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $10.85, but acceptable to hold if already in. Reason: Market cap $368M below $400M minimum.
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with... Read more
Hold if already holding. Not a fresh buy at $10.85, but acceptable to hold if already in. Reason: Market cap $368M below $400M minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $368M below $400M minimum. Not in investable universe. Score 6.2/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 18d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-07-25Recent Developments — Mobia Medical, Inc.
Latest news
- NEWS Mobia Medical Announces Publication Of 2-Yr Follow-Up Data From VNS-REHAB Study In Neurology, Official Peer-Reviewed Jou — benzinga Jul 14, 2026
- NEWS Mobia Medical Says CMS Proposes To Maintain Vivistim CPT Code 64568 Under New Technology APC 1580 With ~$45,000 Outpatie — benzinga Jul 2, 2026 positive
Generated 2026-07-25T09:22:36Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $10.85, but acceptable to hold if already in. Reason: Market cap $368M below $400M minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $368M below $400M minimum. Not in investable universe. Target $14.66 (+35.1%), stop $10.23 (−6.1%), A.R:R 2.3:1. Score 6.2/10, moderate confidence.
Take-profit target: $14.66 (+35.1% upside). Target $14.66 (+35.1%), stop $10.23 (−6.1%), A.R:R 2.3:1. Stop-loss: $10.23.
Market cap $368M below $400M minimum.
Mobia Medical, Inc. trades at a P/E of N/A (forward -5.1). TrendMatrix value score: 6.9/10. Verdict: Hold.
9 analysts cover MOBI with a consensus score of 4.2/5. Average price target: $17.
What does Mobia Medical, Inc. do?Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for...
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.